Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Table 2
Patients attaining an LDL-cholesterol of <70 mg/dL according to their lipid lowering medications.
Lipid-lowering medications
Patients
LDL (mg/dL)
Patients attaining LDL <70
All Patients
9950
82.0 ± 29.2
3555 (36%)
Statin monotherapy
5885
79.8 ± 26.5
2174 (37%)
High potency
1692
81.4 ± 27.0
559 (33%)
Moderate potency
2398
78.7 ± 26.7
946 (39%)
Low potency
1795
79.8 ± 25.7
669 (37%)
Combination therapy*
2730
1119 (41%)
Any statin plus ezetimibe
1378
79.0 ± 28.6
559 (41%)
Any statin plus niacin
866
74.1 ± 24.7
396 (46%)
Any statin plus fibrate
650
81.3 ± 27.6
224 (35%)
No statin
1335
99.9 ± 35.7
262 (20%)
No statin but other lipid-lowering therapy†
389
70 (18%)
Ezetimibe
179
107.1 ± 33.1
20 (11%)
Niacin
113
96.3 ± 36.0
23 (20%)
Fibrate
170
94.3 ± 35.1
39 (23%)
No lipid-lowering therapy
946
99.5 ± 35.5
192 (20%)
*Among patients on a statin plus another lipid-lowering drug 276 patients were on more than one non-statin lipid-lowering drug.
†Among patients on no statin but another lipid-lowering drug, 121 patients were on more than one non-statin lipid-lowering drug. LDL-cholesterol values are expressed as mean ± SD.
